Support throughout your BYOOVIZ treatment

BIOGEN BIOSIMILAR SUPPORT SERVICES
CAN HELP YOU UNDERSTAND YOUR
INSURANCE BENEFITS FOR BYOOVIZ

Biogen Biosimilar Support Services can:

  • Investigate your insurance benefits to help you understand
    your current coverage
  • Provide support in the event of denied insurance claims
  • Educate you on the eligibility details of the Copay Programs,
    which can potentially cover the cost of both your BYOOVIZ
    prescription and treatment procedure
  • Supply background and resources to refer you to third-party
    charitable organizations
  • Connect you and your family to outside resources to explore other
    insurance options
  • Answer other questions you or your family may have about BYOOVIZ
Talk to your healthcare provider for more information about enrolling in Biogen Biosimilar Support Services.

Please note that the Administration Copay Program and Drug Copay Program are different programs with unique eligibility for each. You must enroll separately as needed.

You may be eligible for the Drug Copay Program if you:

  • Have commercial insurance
  • Are a United States resident
  • Are prescribed BYOOVIZ for Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), or Myopic Choroidal Neovascularization (mCNV)
  • Other restrictions apply.*

*There may be an annual cap on the amount of assistance that patients can receive over a one-year period. Your insurance will be billed first and must pay before copay assistance will be applicable. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, VA/DoD, or any other federal plans are not eligible to enroll. Clinical and other restrictions may apply. Patients are eligible to enroll in the Biogen Copay Program for as long as it is offered and they are treated with BYOOVIZ. Please call Biogen Biosimilar Support Services at 1-877-422-8360 for further details.

Please note that the Drug Copay Program and Administration Copay Program are different programs with unique eligibility for each. You must enroll separately as needed.

Individuals on nongovernment insurance may be eligible for the Administration Copay Program, regardless of income. Your healthcare provider must submit a request for treatment using an approved code for administration. Only codes approved by Biogen shall be eligible under the program. Restrictions may apply.

Residents of Massachusetts, Minnesota, or Rhode Island are not eligible. Individuals receiving coverage from Medicare, Medicaid, the VA/DoD, TRICARE®, or any other governmental or pharmaceutical assistance are not eligible. TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.

If it is determined that you are not eligible for Biogen financial assistance, Biogen Biosimilar Support Services may provide information regarding charitable organizations that could potentially provide Third-Party Assistance.

Our Free Drug Program can temporarily provide Biogen products at no cost for individuals who meet certain eligibility criteria such as residency requirements, therapy status, income, and insurance coverage.

Individuals approved and enrolled in the Free Drug Program are required to notify the program if their insurance or financial circumstances change during their enrollment, in order to be reassessed.

Enrolled patients may be contacted periodically during their enrollment to:

  • Check in to see if there have been any changes to their insurance or financial circumstances
  • Evaluate or discuss alternative financial assistance program options
  • Assist in finding new or different insurance if it becomes available

The Free Drug Program only covers the cost of the drug. It does not cover other costs associated with therapy, such as office visits, administration costs, or other professional services.

For more information about these financial assistance options, contact Biogen Biosimilar Support Services at 1-877-422-8360, Monday through Friday, 8:30 AM–8:00 PM ET.